MINERALYS THERAPEUTICS, INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
MINERALYS THERAPEUTICS, INC. (MLYS) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 7.94 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-11
- MINERALYS THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 8.19M shares, a 15.53% increase year-over-year.
- MINERALYS THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 7.09M shares, a 35.79% increase year-over-year.
- MINERALYS THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 5.22M shares, a 42.19% increase year-over-year.
- MINERALYS THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 3.67M shares, a 59.23% decline year-over-year.
- MINERALYS THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 6.70M shares, a 35.96% increase from fiscal 2024.
- MINERALYS THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 4.93M shares, a 38.95% increase from fiscal 2023.
- MINERALYS THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 3.55M shares, a 84.71% decline from fiscal 2022.
- MINERALYS THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 23.20M shares.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|
| 2026-06-30 | 7.94M shares 10-Q · filed 2026-08-11 | |||
| 2026-03-31 | 8.19M shares 10-Q · filed 2026-05-06 | |||
| 2025-12-31 | 6.70M shares 10-K · filed 2026-03-12 | |||
| 2025-09-30 | 6.80M shares 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | 7.24M shares 10-Q · filed 2026-08-11 | |||
| 2025-03-31 | 7.09M shares 10-Q · filed 2026-05-06 | |||
| 2024-12-31 | 4.93M shares 10-K · filed 2026-03-12 | |||
| 2024-09-30 | 5.13M shares 10-Q · filed 2025-11-10 | |||
| 2024-06-30 | 4.94M shares 10-Q · filed 2025-08-12 | |||
| 2024-03-31 | 5.22M shares 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | 3.55M shares 10-K · filed 2025-02-12 | |||
| 2023-09-30 | 3.62M shares 10-Q · filed 2024-11-12 | |||
| 2023-06-30 | 3.74M shares 10-Q · filed 2024-08-13 | |||
| 2023-03-31 | 3.67M shares 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | 23.20M shares 10-K · filed 2024-03-21 | |||
| 2022-09-30 | 23.19M shares 10-Q · filed 2023-11-07 | |||
| 2022-06-30 | 21.62M shares 10-Q · filed 2023-08-07 | |||
| 2022-03-31 | 9.00M shares 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |